U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06800157) titled 'Comparison of LW402 Vs. Placebo, for the Treatment of Rheumatoid Arthritis in China' on Oct. 11, 2024.
Brief Summary: The purpose of this study is to evaluate the dose-response relationship of LW402 tablets in adults with active rheumatoid arthritis combined with methotrexate, in a 12-week therapy
Study Start Date: Feb. 27, 2023
Study Type: INTERVENTIONAL
Condition:
Arthritis, Rheumatoid
Intervention:
DRUG: Drug: LW402
Oral tablets administered BID
DRUG: Other: placebo
Placebo to match LW402 administered BID
Recruitment Status: COMPLETED
Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
Published by HT Digital Cont...